Last reviewed · How we verify
NCT05060796
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
EARLY_PHASE1 trial testing CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells in Non Small Cell Lung Cancer in 11 participants. Currently enrolling.
1 November 2029
Quick facts
| Lead sponsor | Second Affiliated Hospital of Guangzhou Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 11 |
| Start date | 1 September 2019 |
| Primary completion | 1 November 2029 |
| Estimated completion | 1 November 2034 |
| Sites | 1 location across China |
Drugs / interventions tested
- CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Who can join
Adults 18 to 75, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, et al · · 2023 · cited 737× · PMID 36810079 · DOI 10.1186/s12943-023-01740-y -
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3 -
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7 -
Role of chemokine systems in cancer and inflammatory diseases.
Li H, Wu M, Zhao X. · · 2022 · cited 85× · PMID 35702353 · DOI 10.1002/mco2.147 -
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors.
Chen T, Wang M, Chen Y, Liu Y. · · 2024 · cited 77× · PMID 38622705 · DOI 10.1186/s12935-024-03315-3 -
CAR-T cell therapy for lung cancer: Potential and perspective.
Chen L, Chen F, Li J, Pu Y, et al · · 2022 · cited 57× · PMID 35289077 · DOI 10.1111/1759-7714.14375 -
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.
Sun R, Hou Z, Zhang Y, Jiang B. · · 2022 · cited 46× · PMID 36245822 · DOI 10.3892/ol.2022.13528 -
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.
Ma HY, Das J, Prendergast C, De Jong D, et al · · 2023 · cited 35× · PMID 37998743 · DOI 10.3390/cimb45110566
Verify or expand the search:
- PubMed search for NCT05060796
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Second Affiliated Hospital of Guangzhou Medical University trials
Trials by the same sponsor.
- NCT06966830 — Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus · not yet recruiting
- NCT06936683 — Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study） · not yet recruiting
- NCT07374328 — Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus · Phase 1, PHASE2 · recruiting
- NCT06904183 — Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT · Phase 2 · recruiting
- NCT06904196 — Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05060796 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Guangzhou Medical University
- Last refreshed: 25 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060796.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing